Olmesartan Medoxomil/Hydrochloorthiazide Accord (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil blocks the angiotensin II type 1 (AT1) receptors, preventing the hormone from causing blood‑vessel constriction and aldosterone release. This results in vasodilation and reduced fluid retention, which together lower systemic vascular resistance and blood pressure.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s blood‑pressure level, renal function, and other individual factors. The prescriber will select the appropriate strength and frequency according to clinical guidelines.

The safety of this combination during pregnancy has not been established, and it is generally avoided unless the potential benefit outweighs the risk. Limited data are available for breastfeeding; clinicians should evaluate the risk‑benefit ratio before prescribing to nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy, the Olmesartan/HCTZ combination offers dual mechanisms—vascular relaxation from the ARB and diuretic‑induced volume reduction—often resulting in greater blood‑pressure lowering. It may be preferred when a single agent does not achieve target pressure, but clinicians consider individual patient profiles and potential side‑effects.

The product should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the tablets out of reach of children and avoid storing in humid or excessively hot environments.

Olmesartan Medoxomil/Hydrochloorthiazide Accord is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Patients should follow the exact dosing instructions provided on the prescription label.

Serious risks include severe hypotension, hyperkalemia, acute renal failure, and rare cases of angioedema. Patients should be monitored for signs of these conditions, especially during the initial treatment period or when other interacting drugs are used.

The combination is contraindicated in patients with known hypersensitivity to either component, severe renal impairment, or those who are pregnant unless the benefit justifies the risk. It should also be avoided in individuals with hyperkalemia or a history of angioedema related to ARB therapy.